AIDS-related complex ARC

After this initial phase of infection subsides, the free viral load in the blood declines, often to almost undetectable levels. This latent phase may last for anything up to 10 years or more. During this phase, however, there does seem to be continuous synthesis and destruction of viral particles. This is accompanied by a high turnover rate of (CD4+) T-helper lymphocytes. The levels of these T-lymphocytes decline with time, as does antibody levels specific for viral proteins. The circulating viral load often increases as a result, and the depletion of T-helper cells compromises general immune function. As the immune system fails, classical symptoms of AIDS-related complex (ARC) and, finally, full-blown AIDS begin to develop. 

Adachi, M., Hayami, M., Kashiwagi, N., et al. (1988) Expression of LeY antigen in human immunodeficiency virus-infected human T cell lines and in peripheral lymphocytes of patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC). J. Exp. Med. 167(2), 323-331. 

Infection by the virus produces antibodies, but not all of those exposed develop chronic infection. For those that do, AIDS or AIDS-related complex (ARC) bring on a variety of ailments involving the lymph nodes, intermittent fever, loss of weight, diarrhea, fatigue, pneumonia, and tumors. A person infected, known as HIV-positive, can remain disease-free for up to 10 years, as the virus can remain dormant before full-blown AIDS develops. 

Zidovudine has shown activity against human immunodeficiency virus (HIV) consequently, it is used for the treatment of AIDS and AIDS-related complex (ARC). It positively enhanees the survival and improves the quality of life of patients with eomplieations sueh as severe weight loss, fever, pneumocystosis, herpes zoster, herpes or thrush. Beeause it erosses the blood-brain-barrier (BBB), it has a favourable response on the neurological symptoms of AIDS. 

AIDS-immunoglobulins are also known as HTV-immunoglobulins. More recently, AIDS immunoglobulin preparations containing HlV-neutarlizing antibodies have been prepared from the plasma of asymptomatic HfV-positive subject. They are being tried for passive immunization in patients with AIDS or AIDS-related complex (ARC). 

Zidovudine is used in AIDS and AIDS-related complex (ARC) to control opportunistic infections by raising absolute CD4 lymphocyte counts. It was first synthesized in 1964 (81), and its biological activity was reported in 1974 (82). In 1986, Yarchoan et al. (83) demonstrated application of ZDV in clinical trials of AIDS and related diseases. Zidovudine is recommended in the control of the disease in asymptomatic patients in whom absolute CD4 lymphocyte counts are less than 200/mm. It prolongs the life of patients affected with... 

AIDS and AIDS-related complex (ARC) and 3 -azido-2, 3 -dideoxyuridine (7f), l-(3-deoxy-P-D- /ycero-pent-2-eno-furanosyl)thymine (78e) and other related nucleoside derivatives are undergoing preclinical toxicological assays. 

ABG Arterial blood gases ARC AIDS-related complex... 

---